Abstract 4649
Background
Tobacco use has been reported to be the main cause of 90% of male and 80% of female lung cancers, as well as a relevant risk factor for other cancers such as oropharynx, larynx, esophagus, stomach, liver, pancreas, kidney, bladder, and colorectum. Smoking directly affects DNA methylation and although several genes have been reported to be differentially methylated in smokers, gender differences and population-specific differences remain to be further investigated. Our aim was to undertake global and sex-specific genome-wide epigenomic studies (EWAS) in a Mediterranean population to identify the main smoking DNA-methylated genes.
Methods
We analyzed 88 participants in the PREDIMED PLUS-Valencia study paired by age and sex (44 males and 44 females). We included current smokers, former and non-smokers according to the WHO classification. We performed genome-wide DNA methylation using Illumina 850K methylation EPIC arrays. Differential methylation (M-values) was statistically analyzed with Partek, including multivariate adjustement.
Results
In the whole sample, the top-ranked differentially methylated CpG sites (blood) were: cg05575921 in the AHRR (aryl hydrocarbon receptor repressor) gene (P = 2.73E-14), cg21566642 (P = 1.51E-12); cg01940273 (P = 2.10E-10); cg03636183 in the F2RL3 (coagulation factor II thrombin receptor-like 3) gene (P = 6.90E-09); cg23576855 in the AHRR (9.05E-08); and cg17739917 in the RARA (retinoic acid receptor, alpha) gene (P = 1.90E-07), replicating previous finding of the hypomethylation in the AHRR and F2RL3 sites in smokers. In the sex-specific analyses, we detected for both men and women similar hypomethylation in the cg05575921-AHRR site, but some heterogeneity for other loci including the BRCA1 gene.
Conclusions
Smoking has consistent effect of on the methylation of the AHRR gene, but some gender differences for other genes have been detected. This may be related with further gender-smoking differences for some cancers.
Clinical trial identification
2011-005398-22.
Editorial acknowledgement
Legal entity responsible for the study
Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades.
Funding
Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia, Innovación y Universidades.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract
2432 - Retrospective comparative study of the efficacy and safety in docetaxel and ramucirumab combination chemotherapy with or without previous immune checkpoint inhibitor treatment.
Presenter: Daijiro Harada
Session: Poster Display session 1
Resources:
Abstract